Mural Oncology PLC — Investor Relations & Filings
Mural Oncology PLC is a clinical-stage biotechnology company that discovers and develops immunotherapies for cancer treatment. The company leverages its proprietary protein engineering platform to create novel, cytokine-based therapies. Its primary focus is on developing first- and best-in-class drugs for difficult-to-treat tumor types where other immunotherapies, such as checkpoint inhibitors, have not been effective. The company's pipeline is led by nemvaleukin alfa, a novel, engineered IL-2 variant immunotherapy. This candidate is being evaluated in clinical trials for various advanced solid tumors, including platinum-resistant ovarian cancer and advanced melanoma, addressing areas of high unmet medical need.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| DEFA14A | 2025-10-17 | English | |
| DEFA14A | 2025-10-06 | English | |
| Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting | 2025-09-24 | English | |
| DEFA14A | 2025-09-23 | English | |
| DEFA14A | 2025-09-23 | English | |
| DEFA14A | 2025-09-23 | English |
Browse filings by year
3 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 13652251 | DEFA14A | 2025-10-17 | English | ||
| 13652253 | DEFA14A | 2025-10-06 | English | ||
| 7916317 | Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting | 2025-09-24 | English | ||
| 13652255 | DEFA14A | 2025-09-23 | English | ||
| 13652256 | DEFA14A | 2025-09-23 | English | ||
| 13652257 | DEFA14A | 2025-09-23 | English | ||
| 32268487 | DEFM14A Filing | 2025-09-23 | English | ||
| 13652261 | PREM14A | 2025-09-12 | English | ||
| 13652262 | Major Shareholding Notification 2025 | 2025-09-02 | English | ||
| 13652264 | PRIMARY DOCUMENT | 2025-09-02 | English | ||
| 13652265 | DEFA14A | 2025-08-20 | English | ||
| 13652268 | 8-K | 2025-08-20 | English | ||
| 11378040 | Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share | 2025-08-20 | English | ||
| 13652266 | Major Shareholding Notification 2025 | 2025-08-15 | English | ||
| 13652269 | Major Shareholding Notification 2025 | 2025-08-14 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for Mural Oncology PLC, but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
Mural Oncology PLC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/14932/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=14932 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=14932 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=14932 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 14932}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Mural Oncology PLC (id: 14932)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.